Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
catequentinib
- Development stage
- Phase 2
- Lead developer
- Advenchen Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Catequentinib (formerly known as anlotinib in China) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that targets several proteins including vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-3), platelet-derived growth factor receptor beta (PDGFRβ), c-Kit and RET. It is being investigated for its antineoplastic and anti-angiogenic potential across multiple cancer types. The drug is administered orally, typically in a 21-day cycle with 14 days on and 7 days off. Catequentinib is approved in China for the treatment of locally advanced or metastatic non-small cell lung cancer in patients who have undergone progression or recurrence after at least two lines of systemic chemotherapy, as well as for advanced soft-tissue sarcoma.
- Brand names
- Anlotinib
- Other names
- AntinibAnlotinib hydrochloride capsuleAnlotinib Dihydrochloride
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on catequentinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on catequentinib.